- Home
- PPT vs TERN Comparison
PPT vs TERN Comparison
Compare PPT & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPT
- TERN
- Stock Information
- Founded
- PPT 1988
- TERN 2017
- Country
- PPT United States
- TERN United States
- Employees
- PPT N/A
- TERN N/A
- Industry
- PPT Finance Companies
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- PPT Finance
- TERN Health Care
- Exchange
- PPT Nasdaq
- TERN Nasdaq
- Market Cap
- PPT 351.7M
- TERN 321.4M
- IPO Year
- PPT N/A
- TERN 2021
- Fundamental
- Price
- PPT $3.70
- TERN $4.32
- Analyst Decision
- PPT
- TERN Buy
- Analyst Count
- PPT 0
- TERN 5
- Target Price
- PPT N/A
- TERN $15.63
- AVG Volume (30 Days)
- PPT 156.1K
- TERN 895.2K
- Earning Date
- PPT 01-01-0001
- TERN 08-04-2025
- Dividend Yield
- PPT 8.84%
- TERN N/A
- EPS Growth
- PPT N/A
- TERN N/A
- EPS
- PPT N/A
- TERN N/A
- Revenue
- PPT N/A
- TERN N/A
- Revenue This Year
- PPT N/A
- TERN N/A
- Revenue Next Year
- PPT N/A
- TERN N/A
- P/E Ratio
- PPT N/A
- TERN N/A
- Revenue Growth
- PPT N/A
- TERN N/A
- 52 Week Low
- PPT $3.25
- TERN $1.87
- 52 Week High
- PPT $3.72
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- PPT 57.79
- TERN 65.96
- Support Level
- PPT $3.64
- TERN $3.67
- Resistance Level
- PPT $3.67
- TERN $4.39
- Average True Range (ATR)
- PPT 0.03
- TERN 0.31
- MACD
- PPT 0.00
- TERN 0.01
- Stochastic Oscillator
- PPT 77.78
- TERN 91.67
About PPT Putnam Premier Income Trust
Putnam Premier Income Trust is a Massachusetts business trust operating as a non-diversified closed-end management investment company. The fund is currently operating as a diversified fund. Its investment objective is to seek high current income consistent with the preservation of capital by allocating its investments to the U.S. government sector.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.